The Gorlin Syndrome Group has today received a communication from PellePharm regards the status of this global trial. PellePharm want to sincerely thank you for your dedicated partnership and for the community’s ongoing support of our clinical program aimed at developing a therapy for people living with Gorlin syndrome and BCCs.
Under the current pandemic, we have developed a letter to specifically thank and support your membership, from all of us at PellePharm, during this unique and challenging time. The letter gives an update regards the status and arrangements in place for those participating in the trial. To view letter click here